US › Healthcare

Heron Therapeuti (HRTX)

US · Healthcare · Biotechnology

$0.51+0.02%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$34.7M
Revenue YoY
-10.8%
Net profit
$-8.1M
Profit YoY
-407.8%
EPS
$-0.04
EPS estimate
$-0.02
Net margin
-23.4%

EPS came in at -0.04 against a street estimate of -0.02 — a miss of 100.0%.

Key statistics

Market cap
$93.9M
Forward P/E
46.9
P/B
11.61
Book value
$0.04
EPS (TTM)
$-0.18
52-week high
$1.88
52-week low
$0.38
50-day MA
$0.51
200-day MA
$0.99
Beta
1.65

Analyst view

Analysts rate Heron Therapeuti a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $2.00.

Shareholding

Insiders
0.91%
Institutions
82.34%

Largest institutional holders

FundStake
Rubric Capital Management LP15.93%
Clearline Capital LP6.49%
BlackRock Inc5.36%
Vanguard Group Inc5.21%
Orbimed Advisors, LLC5.20%
Velan Capital Investment Management LP4.64%
Vanguard Capital Management, LLC4.14%
Millennium Management LLC4.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Heron Therapeuti — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.